Eli Lilly & Co. (LLY) is rebounding from Friday's sales disappointment, finding support at $722 and set for another uptrend.

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s ...

We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

Conservative commentator Megyn Kelly was seated near the front of a U.S. Senate hearing room Tuesday as former Fox News host Pete Hegseth was grilled by lawmakers. Kelly was seen in the second row of ...

Stay up-to-date with free briefings on topics that matter to all Californians ... The three major brand-name insulin ...

A person who died in a Newport, Washington, house fire last week was identified as 82-year-old James P. Morrison, according to the Spokane County Medical Examiner's Office. The cause and manner of ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

A longtime pharmaceutical executive laments the woeful state of the industry and calls for new leadership to win back public ...

The risk of developing dementia may be much higher than previously thought, a study published Monday in the journal Nature Medicine has found.

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?